文献速递艾滋病与性传播感染

马拉维和赞比亚程序化转换为多替拉韦为基础的一线抗逆转录病毒治疗后的病毒学失败和耐药性

Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia.
PubMed 文献 · Clin Infect Dis · 2025-01-01

在马拉维和赞比亚接受一线非核苷类逆转录酶抑制剂方案治疗的人类免疫缺陷病毒感染者被程序化转换为替诺福韦-拉米夫定-多替拉韦方案。马拉维转换时不考虑病毒载量,赞比亚则要求过去一年病毒载量<1000拷贝/mL。转换时病毒血症与1年和2年病毒血症风险升高相关,赞比亚病毒血症风险低于马拉维,并发现少数多替拉韦耐药突变。

要点

  • 转换时病毒血症与1年病毒血症风险升高相关(调整OR 6.15,95%CI 3.13-11.4)。
  • 赞比亚1年病毒血症风险低于马拉维(OR 0.55,95%CI 0.32-0.94)。
  • 发现2例主要突变导致高水平多替拉韦耐药。

核心结论

  • 将转换为多替拉韦为基础抗逆转录病毒治疗限制在病毒载量<1000拷贝/mL的感染者中可能减少后续病毒血症及多替拉韦耐药突变的出现。

研究设计与样本

  • 比较马拉维(转换时不考虑病毒载量)和赞比亚(转换依赖过去一年病毒载量<1000拷贝/mL)抗逆转录病毒治疗项目的病毒学结局和耐药性。
  • 共纳入2832例人类免疫缺陷病毒感染者(马拉维1422例,赞比亚1410例),中位年龄37岁,2578例(91.0%)为女性。

主要发现

  • 转换时病毒血症(≥400拷贝/mL)在马拉维为77例(5.4%),赞比亚为42例(3.0%)(P = .001)。
  • 转换时病毒血症与1年病毒血症相关(调整OR 6.15,95%CI 3.13-11.4),与2年病毒血症相关(OR 7.0,95%CI 3.73-12.6)。
  • 赞比亚1年病毒血症风险低于马拉维(OR 0.55,95%CI 0.32-0.94),2年风险也低于马拉维(OR 0.33,95%CI 0.18-0.57)。
  • 113份合格样本中79份整合酶测序成功,5例发现耐药突变(马拉维4例,赞比亚1例),其中2例存在主要突变(G118R、E138K、T66A和G118R、E138K)导致高水平多替拉韦耐药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with human immunodeficiency virus (PWH) on first-line, nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy (ART) were routinely switched to tenofovir-lamivudine-dolutegravir. We examined virologic outcomes and drug resistance in ART programs in Malawi, where switching was irrespective of viral load, and Zambia, where switching depended on a viral load <1000 copies/mL in the past year. METHODS: We compared the risk of viremia (≥400 copies/mL) at 1 and 2 years by viral load at switch and between countries using exact methods and logistic regression adjusted for age and sex. We performed HIV-1 pol Sanger sequencing on plasma samples with viral load ≥1000 copies/mL. RESULTS: A total of 2832 PWH were eligible (Malawi 1422, Zambia 1410); the median age was 37 years, and 2578 (91.0%) were women. At switch, 77 (5.4%) were viremic in Malawi and 42 (3.0%) in Zambia (P = .001). Viremia at switch was associated with viremia at 1 year (adjusted odds ratio (OR), 6.15; 95% confidence interval [CI], 3.13-11.4) and 2 years (7.0; 95% CI, 3.73-12.6). Viremia was less likely in Zambia than in Malawi at 1 year (OR, 0.55; 0.32-0.94) and 2 years (OR, 0.33; 0.18-0.57). Integrase sequencing was successful for 79 of 113 eligible samples. Drug resistance mutations were found in 5 PWH (Malawi 4, Zambia 1); 2 had major mutations (G118R, E138K, T66A and G118R, E138K) leading to high-level dolutegravir resistance. CONCLUSIONS: Restricting switching to dolutegravir-based ART to PWH with a viral load <1000 copies/mL may reduce subsequent viremia and, consequently, the emergence of dolutegravir drug resistance mutations. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov (NCT04612452).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Skrivankova VW, Huwa J, Muula G, et al. Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia. Clin Infect Dis. 2025. PMID: 38847281. doi:10.1093/cid/ciae261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。